News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stellar International Inc. (CC:YYS) Enters Into Licensing Agreement With Pharmore GmbH For NeoVisc (R) In Germany



10/19/2005 5:08:46 PM

Stellar International Inc. (TSX VENTURE:SLX) (OTCBB:SLRXF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced that it has signed a Licensing Agreement with Ibbenburen, Germany-based Pharmore GmbH for NeoVisc(R) in Germany. NeoVisc is Stellar's proprietary therapy indicated as a replacement or replenishment ("viscosupplement") for synovial fluid in patients suffering from osteoarthritis ("OA").

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES